Verastem Inc
F:2VSA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Verastem Inc
F:2VSA
|
US |
|
U
|
Unicharm Corp
OTC:UNICY
|
JP |
|
S
|
Silvercorp Metals Inc
AMEX:SVM
|
CA |
|
BHP Group Ltd
ASX:BHP
|
AU |
|
CDW Corp
NASDAQ:CDW
|
US |
|
Coloplast A/S
CSE:COLO B
|
DK |
|
U
|
UOB-Kay Hian Holdings Ltd
XBER:4LJ
|
SG |
|
S
|
Standard Chartered PLC
OTC:SCBFF
|
UK |
|
R
|
RWE AG
OTC:RWNFF
|
DE |
|
Iberdrola SA
OTC:IBDSF
|
ES |
|
Aviva PLC
OTC:AIVAF
|
UK |
|
R
|
Reliance Steel & Aluminum Co
SWB:RS6
|
US |
|
E
|
EDP Energias de Portugal SA
F:EDP
|
PT |
|
Flutter Entertainment PLC
NYSE:FLUT
|
IE |
|
C
|
Cadence Design Systems Inc
XMUN:CDS
|
US |
|
Gismondi 1754 SpA
MIL:GIS
|
IT |
|
Sumitomo Electric Industries Ltd
OTC:SMTOF
|
JP |
|
T
|
Teradyne Inc
F:TEY
|
US |
|
China Mobile Ltd
HKEX:80941
|
CN |
|
T
|
TD Synnex Corp
F:SUX
|
US |
|
Asure Software Inc
NASDAQ:ASUR
|
US |
|
T
|
Tencent Holdings Ltd
SWB:NNN1
|
CN |
Verastem Inc
Verastem is a biotechnology company focused on cancer drugs, especially medicines that target tumors driven by the RAS/MAPK signaling pathway. Its main work is to develop, test, and bring to market prescription therapies for hard-to-treat cancers, with a strong emphasis on ovarian cancer and other solid tumors. In simple terms, it is a drug maker, not a hospital or a research tools company. The company sells its treatments through the medical system, so its main customers are oncologists, cancer centers, hospitals, and the pharmacies and payers that support patient access. Verastem makes money mainly from sales of approved drugs, and it can also earn income from collaboration, licensing, or development agreements tied to its drug pipeline. Because it is a biotech company, a big part of its value comes from whether its clinical programs lead to approved medicines that doctors can prescribe. What makes Verastem different is its narrow focus on a specific cancer biology pathway and on combination therapies, rather than on a broad range of medicines. That gives it a specialized role in the oncology market: it tries to find patient groups that may respond better to targeted treatment and then commercialize those therapies through the standard drug distribution and reimbursement system.
Verastem is a biotechnology company focused on cancer drugs, especially medicines that target tumors driven by the RAS/MAPK signaling pathway. Its main work is to develop, test, and bring to market prescription therapies for hard-to-treat cancers, with a strong emphasis on ovarian cancer and other solid tumors. In simple terms, it is a drug maker, not a hospital or a research tools company.
The company sells its treatments through the medical system, so its main customers are oncologists, cancer centers, hospitals, and the pharmacies and payers that support patient access. Verastem makes money mainly from sales of approved drugs, and it can also earn income from collaboration, licensing, or development agreements tied to its drug pipeline. Because it is a biotech company, a big part of its value comes from whether its clinical programs lead to approved medicines that doctors can prescribe.
What makes Verastem different is its narrow focus on a specific cancer biology pathway and on combination therapies, rather than on a broad range of medicines. That gives it a specialized role in the oncology market: it tries to find patient groups that may respond better to targeted treatment and then commercialize those therapies through the standard drug distribution and reimbursement system.
Revenue: Verastem reported $18.7 million of net product revenue in Q1 2026 from the AVMAPKI FAKZYNJA CO-PACK launch, with management saying sales have grown quarter over quarter since launch.
Launch reset: Management said Q1 was affected by seasonal insurance turnover, reverifications, and weather, and also by some earlier-than-expected discontinuations in sicker patients. The company has made targeted commercial changes, including naming a new Chief Commercial Officer and adding sales coverage.
2026 outlook: Management expects the LGSOC franchise to become self-sustaining in the second half of 2026, with CO-PACK revenue covering commercial costs and ongoing avutometinib plus defactinib trials.
VS-7375: Verastem said its KRAS G12D program is advancing in parallel across pancreatic, lung, and colorectal cancer, with first patients in the Phase II studies expected mid-year or sooner.
Go-forward dose: The company said updated PK data support 900 milligrams as the likely go-forward dose, while 1,200 milligrams is being evaluated but is limited by current pill size and practical dosing.
Cash runway: Verastem ended Q1 with $181.7 million in cash, cash equivalents, and investments, and said that together with product revenue this should fund operations into the first half of 2027.
